PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.88%
Positive revenue growth while 3141.T is negative. John Neff might see a notable competitive edge here.
5.75%
Positive gross profit growth while 3141.T is negative. John Neff would see a clear operational edge over the competitor.
12.67%
Positive EBIT growth while 3141.T is negative. John Neff might see a substantial edge in operational management.
12.67%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
-3.27%
Negative net income growth while 3141.T stands at 1.22%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3.27%
Negative EPS growth while 3141.T is at 0.97%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3.27%
Negative diluted EPS growth while 3141.T is at 0.90%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3141.T is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.32%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.34%
10Y revenue/share CAGR under 50% of 3141.T's 159.18%. Michael Burry would suspect a lasting competitive disadvantage.
48.58%
5Y revenue/share CAGR at 75-90% of 3141.T's 60.00%. Bill Ackman would encourage strategies to match competitor’s pace.
25.30%
3Y revenue/share CAGR similar to 3141.T's 27.19%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.18%
Below 50% of 3141.T's 324.46%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
39.74%
5Y net income/share CAGR at 75-90% of 3141.T's 45.84%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
28.36%
3Y net income/share CAGR above 1.5x 3141.T's 16.15%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
151.08%
10Y equity/share CAGR at 50-75% of 3141.T's 272.16%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
101.86%
5Y equity/share CAGR 1.25-1.5x 3141.T's 72.58%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
50.02%
3Y equity/share CAGR 1.25-1.5x 3141.T's 40.33%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.35%
Our AR growth while 3141.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-2.20%
Inventory is declining while 3141.T stands at 5.70%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.82%
Asset growth well under 50% of 3141.T's 6.63%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.57%
1.25-1.5x 3141.T's 1.73%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-57.60%
We’re deleveraging while 3141.T stands at 27.58%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
83.47%
We expand SG&A while 3141.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.